Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | CBFB | Q13951 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721156 | 0.85 | CLK1 (0.41) | PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL2719397 | 0.83 | METAP1 (0.41) | METAP1LMNAL3MBTL1 | |
| SCHEMBL10200560 | 0.83 | METAP1 (0.41) | METAP1LMNAL3MBTL1 | |
| SCHEMBL6121710 | 0.82 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CBPIK3CAMETAP2 | |
| SCHEMBL2720782 | 0.79 | CCR1 (0.38) | PIK3CDPIK3CGPIK3CBPIK3CACBFB | |
| SCHEMBL2718744 | 0.79 | GRM5 (0.40) | PIK3CDPIK3CGPIK3CBPIK3CALMNA | |
| SCHEMBL10199790 | 0.79 | GRM5 (0.40) | PIK3CDPIK3CGPIK3CBPIK3CALMNA | |
| SCHEMBL20061345 | 0.79 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CBPIK3CAMETAP2 | |
| SCHEMBL28565071 | 0.79 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CBPIK3CAMETAP2 | |
| SCHEMBL2718453 | 0.76 | HPGDS (0.43) | METAP2METAP1CBFBLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2635565-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | Amgen Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061696-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | AMGEN INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061696-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | AMGEN INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | PIK3CD 1672/4885PIK3CG 2394/4885PIK3CB 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.